Compare Amgen, Inc. (AMGN) vs ConocoPhillips (COP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs ConocoPhillips — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while ConocoPhillips trades at $110.45 (market cap $132.84B). The key difference: Amgen, Inc. is the larger of the two by market cap, and ConocoPhillips pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| AMGN | COP | |
|---|---|---|
Market Cap | $196.12B | $132.84B |
Sector | Health | Energy |
52-Week High | $388.16 | $133.80 |
52-Week Low | $271.18 | $85.66 |
Enterprise Value | $241.41B | $149.81B |
Dividend Yield | 2.77% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ConocoPhillips (COP) trades at $109.04, up 0.94% with a bullish technical signal despite mixed moving averages. The company maintains solid fundamentals with $58.94B revenue, 12.58% net margin, and consistent cash flow generation. Recent earnings show beats in Q3 2025 and Q1 2026, while analysts project strong Q2 2026 EPS of $2.85. The stock offers a dividend yield with recent $0.84 payout, supported by 74.51% buy ratings from coverage analysts.
COP presents a compelling value opportunity with P/E of 18.48 and EV/EBITDA of 6.08 below sector averages. The consensus price target of $137.14 implies 26% upside potential. Key risks include oil price volatility, geopolitical tensions affecting Middle East supply, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The upcoming Q2 earnings on August 6, 2026, will be crucial for validating growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
